Kathy Ivey
About Kathy Ivey
Kathy Ivey serves as the Vice President of Gene Therapy Research at Tenaya Therapeutics, a position she has held since 2022. She has extensive experience in gene therapy, having previously worked in various roles at Tenaya Therapeutics and Gladstone Institutes over a span of several years.
Work at Tenaya Therapeutics
Kathy Ivey currently serves as the Vice President of Gene Therapy Research at Tenaya Therapeutics. She has held this position since 2022, contributing to the company's focus on innovative gene therapies. Prior to her current role, she was the Senior Director of Gene Therapy Biology at the same organization from 2020 to 2022. During her tenure, she has played a significant role in advancing the company's research initiatives in gene therapy.
Previous Experience at Gladstone Institutes
Before joining Tenaya Therapeutics, Kathy Ivey worked at Gladstone Institutes in various capacities. She served as a Staff Research Scientist III for one year in 2015 to 2016. Additionally, she held the position of Staff Research Investigator and Stem Cell Core Director from 2009 to 2014. Earlier in her career at Gladstone, she was a Research Scientist from 2005 to 2009. Her experience at Gladstone Institutes contributed to her expertise in gene therapy and stem cell research.
Education and Expertise
Kathy Ivey earned her PhD in Biomedical Science from UT Southwestern Medical Center, where she studied from 1999 to 2004. This educational background provided her with a solid foundation in biomedical research, which she has applied throughout her career in gene therapy and related fields. Her academic training has been instrumental in her roles within the biotechnology sector.
Career Progression in Gene Therapy
Kathy Ivey has a progressive career in gene therapy, beginning with her role as a Research Scientist at Gladstone Institutes from 2005 to 2009. She then advanced to Director of Gene Therapy Biology at Tenaya Therapeutics from 2016 to 2020. Her experience in various roles has allowed her to develop a comprehensive understanding of gene therapy research, leading to her current position as Vice President.